ABL1 and acute myeloid leukemia: Three (60.0%) of the five patients not treated with TKI before allo‐HCT and only one (5.9%) of the 17 patients treated with TKI had non‐CR at transplantation in the AML with BCR::ABL1 group (p = 0.024).